Expiration of warrants

EDX Medical Group PLC

04 June 2026

 

​

June 4, 2026

EDX Medical Group plc

("EDX Medical" or the "Company")

Expiration of warrants

CAMBRIDGE, UK: EDX Medical Group plc (AIM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces the expiration of all warrants over ordinary shares in EDX Medical as of 5pm yesterday, June 3rd, 2026, in accordance with the terms of the warrant instrument.

Prior to the expiration deadline, one warrant holder exercised their rights resulting in the issue of 150,000 new ordinary shares at an exercise price of 10p per ordinary share. Application has been made for 150,000 ordinary shares to be admitted to trading on AIM and it is expected that trading will commence on 9 June 2026.

Following this issue of ordinary shares the Company will have 411,994,583 ordinary shares in issue. This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company or its Group under the FCA's Disclosure and Transparency Rules.

ENDS

For enquiries, please contact:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations)
Graham Herring Tim Metcalfe	[phone]

 About EDX Medical Group plc

The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

 

END